Video Series

An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.

The expert panel discuss the importance of legislative support to continue innovations in the biosimilar space.

The expert panel discuss future trends in the biosimilar space.

Reynold A. Panettieri Jr., MD, elaborates on the risks of lung damage resulting from exacerbations, with a focus on the role of type 2 inflammation in triggering these events.

A key opinion leader examines the etiology of asthma and potential risk factors for COPD development, emphasizing the role of environmental exposures.

A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.

The panel discusses ideal goals for biosimilar utilization.

Dr. Tichy discusses unmet needs he deems crucial for the continued uptake of biosimilars.

Key opinion leaders explore molecular characteristics beyond mutations that influence immunotherapy response in non small cell lung cancer treatment.

Jonathan Silverberg, MD, PhD, MPH, examines the significant effects of chronic skin conditions such as atopic dermatitis and prurigo nodularis on patients' well-being, emphasizing the crucial role of prompt diagnosis in managing these impactful dermatologic diseases.

Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.

The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.

Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.

Dr Nathan provides his final thoughts regarding IPF management.

Dr Nathan discusses the trajectory of IPF management.

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.

Dr Nathan highlights the role of PDE4B inhibitors in IPF management.

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.

A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings.

The panel discusses out of pocket costs and the impact of the 340b program for various patient types.

The panel discusses how employer preferences influence the strategies and decisions of payers/PBMs.

Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.

A panel of experts discuss using systemic corticosteroids in CSU treatment.

A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.

Stanley Goldstein, MD, discusses which therapies are typically used initially for CSU patients.

A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU.